<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02324985</url>
  </required_header>
  <id_info>
    <org_study_id>AP-005</org_study_id>
    <nct_id>NCT02324985</nct_id>
  </id_info>
  <brief_title>Phase II Study of AP0302 5% Versus a Vehicle Comparator</brief_title>
  <official_title>Phase II Study of the Effects of AP0302 5% Versus the Vehicle Control on Delayed Onset Muscle Soreness of the Elbow Flexors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aponia Laboratories, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aponia Laboratories, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the analgesic safety and efficacy of study drug (AP0302)
      applied topically every 6 hours as compared to a vehicle, in subjects experiencing delayed
      onset muscle soreness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel
      5% in reducing pain/soreness associated with delayed onset muscle soreness (DOMS).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sum of pain intensity differences over 24 hours from baseline (SPID24) with movement</measure>
    <time_frame>0-24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sum of pain intensity differences over 48 hours from baseline (SPID48) with movement</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sum of pain intensity differences over 48 hours from baseline (SPID48) at rest</measure>
    <time_frame>0-48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Pain</condition>
  <condition>Delayed Onset Muscle Soreness</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>S-Ibuprofen Topical Gel 5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle Topical Gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-Ibuprofen Topical Gel 5%</intervention_name>
    <description>S-Ibuprofen Topical Gel 5% applied every 6 hours</description>
    <arm_group_label>Active Arm</arm_group_label>
    <other_name>Active Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Topical Gel</intervention_name>
    <description>Vehicle Topical Gel applied every 6 hours</description>
    <arm_group_label>Placebo Arm</arm_group_label>
    <other_name>Vehicle Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  no clinically significant medical conditions

          -  BMI between 18-30

          -  negative drug, alcohol, pregnancy screens

          -  other protocol-defined inclusion criteria may apply

        Exclusion Criteria:

          -  no upper extremity workout in last 6 months

          -  no job requiring heavy lifting

          -  history of muscle disorders

          -  allergy or intolerance to study drug

          -  history of recent pain medication use

          -  other protocol-defined exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonia Singla, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lotus Clinical Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kenneth M Corroon, Chief Executive Officer</last_name>
    <email>kcorroon@aponialabs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>January 12, 2015</last_update_submitted>
  <last_update_submitted_qc>January 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>muscle soreness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myalgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

